The primary role of Paracetamol comp. STADA is to provide targeted symptomatic relief in contexts where patients experience symptoms that interfere with daily functioning. The combination of its active components is applied in addressing symptom clusters that may become intense or disruptive. The combination of acetaminophen (paracetamol) and codeine is commonly used to help with pain, and its acetaminophen component is also relevant for easing symptoms related to systemic imbalance, such as fever.

The medication is generally used to help manage moderate pain associated with conditions like significant dental discomfort, acute tension headaches, or moderate musculoskeletal aches. It is also applied during acute symptomatic episodes like flu-like infections or in situations involving episodic or fluctuating manifestations, such as post-procedural discomfort.

“The combination is considered relevant when supportive symptom management is appropriate, particularly when the level of discomfort is used when symptoms require additional symptomatic assistance.”

The product provides support that helps ease the overall symptom burden and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Moderate Pain
This combination is relevant when pain intensity creates noticeable physiological strain and is applied in scenarios where additional management of discomfort is required.

Regulatory References

1. NIH MedlinePlus overview

This section describes the eligibility criteria and prohibitions for using this Codeine and Paracetamol combination, as officially mandated by government regulatory agencies. The restrictions are primarily related to the Codeine component.

Contraindicated Populations (Must Not Use)

Category	Regulatory Status
Pediatric Age	Children younger than 12 years of age.
Specific Surgery	Paediatric patients (0–18 years) post-tonsillectomy/adenoidectomy for obstructive sleep apnoea syndrome.
Genetic Status	Patients known to be CYP2D6 ultra-rapid metabolizers.
Maternal Status	Women who are breastfeeding.
Severe Organ Function	Patients with severe hepatic insufficiency or acute respiratory depression.

Restricted or Conditional Use

Usage requires caution and may necessitate dose reduction or supervision in the following groups, as stated in regulatory labels:

• Adolescents (12–18 years): Not recommended if the patient has compromised respiratory function (e.g., severe lung disease, obesity).
• Organ Impairment: Patients with severe renal impairment or impaired liver function.
• Geriatric Patients: Caution is advised due to increased sensitivity to opioid effects.
• Comorbidities: Conditions such as raised intracranial pressure, prostatic hypertrophy, or hypothyroidism require cautious use.

Interactions with other medicines and products

This medication should not be used in combination with any other product containing paracetamol due to the serious risk of liver damage from exceeding the maximum recommended daily dose. Regular or excessive consumption of alcohol is also restricted, as it may potentiate paracetamol's hepatotoxicity by increasing the production of a toxic metabolite.

Clinically Relevant Interactions

• Anticoagulants (e.g., warfarin): Prolonged regular daily use of paracetamol may enhance the anticoagulant effect, increasing the risk of bleeding. Occasional doses are generally considered safe.
• Liver Enzyme Inducers: Certain medicines, including some antiepileptics (e.g., phenobarbital, phenytoin, carbamazepine), rifampicin, and tricyclic antidepressants, can increase the formation of paracetamol’s toxic metabolite, thus enhancing the risk of liver damage.
• Flucloxacillin: Concurrent use has been associated with a risk of High Anion Gap Metabolic Acidosis (HAGMA), particularly in patients with pre-existing risk factors such as malnutrition or severe kidney impairment.
• Probenecid: This medicine reduces the clearance of paracetamol from the body. A dose reduction of paracetamol may be necessary when taken concomitantly.
• Absorption Rate Modifiers: Drugs that increase gastric emptying, such as metoclopramide or domperidone, can increase the absorption rate of paracetamol. Conversely, cholestyramine reduces absorption if administered within one hour of paracetamol.
• Zidovudine: Chronic, simultaneous use may increase the risk of neutropenia.

Dual Inhibition of Prostaglandin Synthesis (COX Pathways)

This mechanism involves Propyphenazone and Paracetamol inhibiting Cyclooxygenase (COX) enzymes. This action reduces the synthesis of prostaglandins ( PGE2) in both central and peripheral tissues. The resulting effect is a re-setting of the hypothalamic thermal set-point and a reduction in nociceptor sensitization.

---

Modulation of Central Nociceptive Pathways (Non-COX)

The Paracetamol component also modulates signaling pathways within the Central Nervous System (CNS), independent of its COX inhibition. This involves the active metabolite, AM404, which engages TRPV1 and CB1 receptors. This central interaction contributes an additional, non-prostaglandin-driven modulation of ascending pain signals by engaging descending nociceptive-regulating pathways that originate in the brain and project to the spinal cord.

---

Adenosine Receptor Antagonism (Adjuvant Effect)

Caffeine acts as an adjuvant by antagonizing adenosine receptors in the CNS and vascular system. This mechanism causes cerebral vasoconstriction (narrowing of blood vessels in the brain). These physiological changes influence the pharmacodynamics of the active components and are relevant in systems sensitive to vascular tone.

Official Administration Guidelines

The usage of Paracetamol comp. STADA, a fixed-dose combination oral product, is defined by strict regulatory parameters concerning dose, frequency, and maximum exposure, intended for short-term, intermittent use. The product is for oral administration only.

---

Administration Scope	Official Regulatory Principle
Standard Adult Dosing	The typical single adult dose is one to two tablets. The dose is administered up to four times per day.
Dosing Frequency	Doses must be separated by a minimum time interval of four to six hours. The total daily intake must not exceed eight tablets in a 24-hour period.
Maximum Duration	Use should be limited to a maximum of three consecutive days without a medical review. If long-term use is necessary, gradual dose tapering is indicated for discontinuation.

The tablets may be swallowed whole with water and taken with or without food.

---

Population-Specific Instructions

Regulatory documents outline mandatory adjustments for certain patient groups. The medicine is contraindicated for all children younger than 12 years of age. For patients with hepatic or renal impairment, the dose should be reduced or the interval between doses must be prolonged to account for reduced drug clearance. It is essential not to use this medicine concurrently with any other products containing Paracetamol or Codeine to avoid exceeding the maximum component doses.

Research Evidence / Overview of Studies for Paracetamol comp. STADA

---

Evidence for Use in Acute Moderate Pain

The clinical research framework for the Acetaminophen/Codeine combination primarily consists of Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that synthesize the findings of these trials. Research has been conducted in the context of acute, short-term discomfort, including settings involving postoperative pain following procedures such as dental or general surgery.

Studies typically examined outcomes related to physical discomfort, monitoring patient-reported outcomes describing perceived discomfort over defined time intervals. Research has explored the combination's role in settings where symptoms were heightened. Findings describe patterns observed in the studies where the combination's results were noted to differ in measured pain scores over a short time interval when evaluated against an inactive control.

---

Comparisons with Other Analgesics and Placebo

A significant portion of the evidence base was studied in trials against a placebo (an inactive substance) and against single-ingredient acetaminophen alone. In these comparative studies, research reported a difference in the proportion of patients reporting a specific level of pain relief over a few hours when compared with the inactive control.

Other research has explored the combination against non-opioid analgesics, such as NSAIDs. For some acute scenarios, research explores whether the combination's measured analgesic outcomes aligned with those of non-opioid options. This research contributes to the broader evidence landscape by providing context on how the combination was studied relative to other pain management strategies examined in clinical trials.

---

What is Still Uncertain About the Research Base

Research highlights what is known—and what is still uncertain. Findings indicate that the pain relief reported in studies may be influenced by inter-individual variability, which affects how individuals respond. This variability contributes to uncertainty when predicting individual patient outcomes.

Long-term effects are not fully established, as evidence has primarily explored the drug in research scenarios examining temporary physiological imbalance and acute episodes. There is limited information for long-term outcomes or data on conditions that require extended symptomatic assistance. Additionally, the evidence base for the combination’s effect on certain chronic pain conditions remains insufficient. Research describes group patterns, not personal outcomes, and does not determine whether an individual will respond similarly outside of the specific conditions under which the studies were conducted.

Common questions about Paracetamol comp. STADA (FAQ)

Q: Why is this medication called 'comp.' (compound)?

The abbreviation 'comp.' in the drug's name often stands for 'compound' or 'compositum.' According to the official product information, this term is used to signal that the medication is a fixed-dose combination product containing more than one active pharmaceutical ingredient. This classification differentiates it from single-ingredient formulations.

Q: Is Paracetamol comp. STADA a prescription-only medicine?

The legal status of Paracetamol comp. STADA depends on the specific country's regulatory classification. Regulatory authorities determine if the drug is categorized as a Prescription Only Medicine (POM) or if it is approved to be sold over the counter (OTC) without a prescription. This classification is listed in the medication's marketing authorization status.

Q: How quickly is the effect of Paracetamol comp. STADA generally expected to begin?

Regulatory summaries typically provide information on how quickly the medication is expected to begin working. The onset of the pain-relieving action for the paracetamol component is usually described as starting within 30 to 60 minutes after the tablet is taken.

Q: How long is the duration of action for Paracetamol comp. STADA typically described as lasting?

The expected duration of effect is indirectly addressed through the mandated dosing schedule. Official dosing instructions specify that doses must be separated by a minimum interval of four to six hours. This interval is set to ensure the components maintain their therapeutic concentration while preventing drug accumulation.

Q: Is it possible to use Paracetamol comp. STADA if I have a sensitive stomach?

The paracetamol component is generally associated with a favorable profile regarding the stomach lining compared to some other analgesic classes. However, the Codeine component is known to potentially cause common gastrointestinal side effects, such as nausea or constipation. Specific warnings for patients with pre-existing stomach sensitivity are detailed within the official product information.

Q: Do official documents mention any common concerns regarding side effects for Paracetamol comp. STADA?

Official documents categorize side effects by how frequently they are reported. While specific severe side effects are detailed under the 'Rare' or 'Very Rare' classifications, common reported effects often include general discomfort such as gastrointestinal issues, nausea, vomiting, or abdominal pain.

Q: Are there any widely reported interactions between Paracetamol comp. STADA and caffeine intake?

Regulatory information indicates that the formulation already contains an adjuvant ingredient (Caffeine). For this reason, official product warnings exist regarding the use of additional products that contain caffeine while taking this medicine.

Q: Is there a known risk of dependence associated with Paracetamol comp. STADA?

Due to the presence of the Codeine component, which is an opioid analgesic, the product label includes specific warnings. These official statements address the potential for abuse and the development of dependence, particularly when the medicine is used for prolonged periods.

Q: Does taking Paracetamol comp. STADA affect the results of any common lab tests?

Official regulatory information states that some common laboratory tests may be affected by the use of paracetamol. Specifically, the paracetamol component has been shown to potentially interfere with the results of certain medical tests, such as some types of blood glucose measurements. Disclosure of all current medications to laboratory staff is required before testing, according to official guidance.

Q: What are the ingredients that make Paracetamol comp. STADA a 'compound' preparation?

The term 'compound preparation' refers to both the active ingredients (Paracetamol and Codeine) and the non-active components, or excipients. The full list of excipients, which may include stabilizing agents or fillers, is provided in Section 6.1 (List of Excipients) of the official product document.

Q: Is it common for people to report feeling drowsy after using Paracetamol comp. STADA?

Regulatory product information does list somnolence, which means drowsiness, as a potential side effect. This is particularly noted as a risk associated with the opioid (Codeine) component of the combination drug.

Q: Can Paracetamol comp. STADA cause stomach upset or digestive issues?

Yes, common gastrointestinal side effects are listed in the product’s safety profile, categorized by regulatory authorities. These potential issues include nausea, vomiting, or constipation, with the latter being a known effect related to the opioid analgesic component.

Q: What is the official guidance on using Paracetamol comp. STADA for migraine headaches?

The therapeutic indications section of the product label lists the specific conditions for which the drug is authorized to provide relief. If officially indicated, the label will explicitly mention conditions like migraines or tension headaches as appropriate uses for this product.

Q: Are there any dietary restrictions mentioned in the official literature for Paracetamol comp. STADA?

The primary dietary restriction emphasized in official regulatory warnings is the concurrent or excessive consumption of alcohol. This warning is in place because alcohol intake may increase the risk of severe liver damage associated with the paracetamol component.

Q: Does Paracetamol comp. STADA contain any common allergens like lactose or gluten?

Official regulatory documents must provide a complete listing of all excipients, or non-active components, used in the final product. This list, found in Section 6.1, allows patients to check for the presence of common allergens, such as lactose or gluten.

Q: Where can I find the official regulatory document (like the SmPC or Package Leaflet) for this medicine?

The official regulatory documents, such as the Summary of Product Characteristics (SmPC) or the Package Leaflet, are published by national or regional medicines regulatory authorities. These documents can typically be found on the websites of bodies like the European Medicines Agency (EMA) or the Food and Drug Administration (FDA) for the relevant country.

Q: Does the medicine come in different formulations, such as tablets or effervescent powder?

The official document confirms that the authorized pharmaceutical form for this specific product is the oral tablet. Information regarding any other forms, such as effervescent powder, capsules, or syrups, would be explicitly listed in regulatory Section 3 if they were authorized.

Q: Can Paracetamol comp. STADA be used by individuals with high blood pressure?

Regulatory warnings include cautionary statements regarding use in patients with pre-existing cardiovascular conditions, including high blood pressure. These warnings are included to ensure appropriate risk consideration of the combined ingredients.

Q: Do official summaries mention anything about potential cardiovascular side effects?

Potential adverse reactions are categorized by regulatory authorities into System-Organ-Classes. This categorization ensures that any effects relating to the cardiovascular system, such as changes in blood pressure or heart rate, are documented and listed in the side effects section of the label.

Q: Is it true that this drug can affect sleep?

The regulatory document lists somnolence, or drowsiness, as a potential side effect of this medicine. Due to this potential for altered consciousness, the drug may consequently affect a user's normal sleep patterns or alertness.

Q: What information is available regarding the effect of Paracetamol comp. STADA on alertness?

Official product information includes a specific section detailing the potential effects of the medicine on the user’s ability to drive and operate machinery. This information is particularly important because the Codeine component is known to potentially impair alertness and reaction time.

Q: What are the signs of a serious allergic reaction associated with this medication, as described by regulators?

Regulatory documents describe serious allergic reactions such as anaphylaxis and severe skin reactions. Signs to be aware of include swelling of the face, throat, or tongue, difficulty breathing, and the development of a raised or blistering rash.

Q: Can Paracetamol comp. STADA be used by people with a history of asthma?

Official warnings advise that caution should be exercised for use in patients with a history of compromised respiratory function. The Codeine component is known to affect the respiratory system, making conditions like asthma a factor that requires careful consideration.

Q: Are there any studies exploring the use of this drug in pediatric populations?

Clinical research data related to the use of the combination drug in the authorized pediatric population (adolescents aged 12 to 18) are typically summarized in the drug’s clinical properties section. These studies provide context on the safety and efficacy patterns observed in this age group during clinical trials.

Q: What are the known potential effects on the nervous system?

Due to the active components acting on the Central Nervous System (CNS), potential effects are documented in regulatory summaries. These effects may include nervous system disorders such as headaches, dizziness, and somnolence (drowsiness).

Official Storage and Disposal Requirements

Regulatory documentation defines strict guidelines for the storage and disposal of this medicine, particularly due to the presence of the opioid analgesic Codeine.

Requirement Area	Official Instructions
Storage Environment	Store at room temperature, protected from heat, moisture, and direct light. Do not freeze.
Container & Stability	Keep the medicine in its original, closed container and do not use past the expiry date shown on the packaging.
Security & Access	Must be kept out of the sight and reach of children and stored securely in a location inaccessible to others.
Disposal Protocol	Unused or expired product must not be discarded via household waste or wastewater. Dispose of the medicine in accordance with national requirements, typically via an official drug take-back program.